SPARC and familial pancreatic carcinoma: Mean plasma levels of the examined molecules and their statistical comparison between healthy individuals and patients with pancreatic cancer are depicted in Figure 1A and B. Our analysis demonstrated that, among all examined substances, in comparison to healthy controls, significantly lower osteonectin and higher osteopontin levels were observed in patients with pancreatic adenocarcinoma.